JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

This study tests JY231, an experimental CAR-T cell therapy — immune cells engineered to fight cancer — in adults with blood cancers (B-cell lymphoma or leukemia) that have come back or stopped responding to prior treatment. The therapy targets a protein called CD19 found on cancer cells. **You may be eligible if...** - You are 18–75 years old - You have confirmed B-cell lymphoma or leukemia that is relapsed or refractory (stopped responding to treatment) - Your cancer cells test positive for CD19 - You have already tried at least one prior treatment - Your overall health and organ function are adequate **You may NOT be eligible if...** - You have received prior CAR-T therapy targeting CD19 - You have active serious infections (including HIV or hepatitis) - You have significant heart, lung, liver, or kidney problems - You have active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.